Attention: You are using an outdated browser, device or you do not have the latest version of JavaScript downloaded and so this website may not work as expected. Please download the latest software or switch device to avoid further issues.

News > Community news > Crick spinout to begin first-in-human clinical study for leukaemia

Crick spinout to begin first-in-human clinical study for leukaemia

GammaDelta Therapeutics has received Investigational New Drug approval from the US FDA for their GDX012 cell therapy to be investigated as a treatment for blood cancers. 
7 Jun 2021
United States of America
Community news

Featured

Clinicians

To view this News Article please log in or create a profile

Similar stories

Community news

€9.8m ERC Synergy grant awarded to study how human tissues stay healthy as we age

More...
Simon Boulton named as Cancer Research UK's Chief Translation Advisor

More...

Jean Langhorne and Soly Ismail
2024 Crick Translation Prize jointly awarded to Jean Langhorne and Robert Wilkinson, and Soly Ismail

More...

Paul Nurse, our Director and CEO, has been elected as the next President of the Royal Society.
Paul Nurse elected as President of the Royal Society

More...

Science educator Andy Harrison teaching in the Crick's Weston Discovery lab
Education outreach from the Crick

Science educator Andy Harrison teaching in the Crick's Weston Discovery lab More...

Have your say

 
image

Contact us

The Francis Crick Institute
1 Midland Road
London
NW1 1AT

connect@crick.ac.uk


Check out

Community
Mentoring
Careers
News
Groups
Events

Legal

Terms
Privacy
Cookies
About
Contact

This website is powered by
ToucanTech